111 related articles for article (PubMed ID: 27159935)
21. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
Bayram M; De Luca L; Massie MB; Gheorghiade M
Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
[TBL] [Abstract][Full Text] [Related]
22. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy.
Bhat G
ASAIO J; 2006; 52(6):677-81. PubMed ID: 17117058
[TBL] [Abstract][Full Text] [Related]
23. OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization.
Gheorghiade M; Gattis WA; Klein L
Eur J Heart Fail; 2003 Jan; 5(1):9-12. PubMed ID: 12559209
[No Abstract] [Full Text] [Related]
24. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
Varriale P; Ramaprasad S
Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of patients with right ventricular failure on milrinone after left ventricular assist device implantation.
Tsiouris A; Paone G; Brewer RJ; Nemeh HW; Borgi J; Morgan JA
ASAIO J; 2015; 61(2):133-8. PubMed ID: 25551415
[TBL] [Abstract][Full Text] [Related]
26. Home inotropic therapy in children.
Berg AM; Snell L; Mahle WT
J Heart Lung Transplant; 2007 May; 26(5):453-7. PubMed ID: 17449413
[TBL] [Abstract][Full Text] [Related]
27. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
28. Is monitoring milrinone therapy useful in advanced heart failure?
Vazir A; Leaver N; Lyster H; Alexanian A; Wilton P; Banner NR
Int J Cardiol; 2011 Jun; 149(3):380-1. PubMed ID: 21450357
[No Abstract] [Full Text] [Related]
29. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction.
Cox ZL; Calcutt MW; Morrison TB; Akers WS; Davis MB; Lenihan DJ
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):433-8. PubMed ID: 23695773
[TBL] [Abstract][Full Text] [Related]
30. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
Klein L; Massie BM; Leimberger JD; O'Connor CM; Piña IL; Adams KF; Califf RM; Gheorghiade M;
Circ Heart Fail; 2008 May; 1(1):25-33. PubMed ID: 19808267
[TBL] [Abstract][Full Text] [Related]
31. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times.
Assad-Kottner C; Chen D; Jahanyar J; Cordova F; Summers N; Loebe M; Merla R; Youker K; Torre-Amione G
J Card Fail; 2008 Dec; 14(10):839-43. PubMed ID: 19041047
[TBL] [Abstract][Full Text] [Related]
32. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
[TBL] [Abstract][Full Text] [Related]
33. Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Hollander SA; Wujcik K; Schmidt J; Liu E; Lin A; Dykes J; Good J; Brown M; Rosenthal D
J Pain Symptom Manage; 2023 Mar; 65(3):216-221. PubMed ID: 36417945
[TBL] [Abstract][Full Text] [Related]
34. When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Ahmad T; Patel CB; Milano CA; Rogers JG
Circulation; 2012 Jun; 125(23):2948-55. PubMed ID: 22689932
[No Abstract] [Full Text] [Related]
35. A bridge for the 21st century in heart transplantation?
Felker GM; O'connor CM
Am Heart J; 2003 Feb; 145(2):198-9. PubMed ID: 12595831
[No Abstract] [Full Text] [Related]
36. Myocardial and vascular effects of intracoronary versus intravenous milrinone.
Colucci WS; Ludmer PL; Wright RF; Arnold JM; Ganz P; Braunwald E
Trans Assoc Am Physicians; 1985; 98():136-45. PubMed ID: 3842193
[No Abstract] [Full Text] [Related]
37. [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure].
Gun C; Piegas LS; Bianco AC; Freire RB; Ramos RF; Timerman A
Arq Bras Cardiol; 1995 Sep; 65(3):255-8. PubMed ID: 8579514
[TBL] [Abstract][Full Text] [Related]
38. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
39. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
40. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
